Shots:

• Silence to receive $60M upfront- $20M equity investment- $10M as an option fee/ selected target- ~$140M as development milestones- ~$250M as commercial milestones for each target along with royalties on sales of the therapies
• The multi-target alliance is expected to initially work on 5 targets within the first 3yrs. of the collaboration with AstraZeneca to get an option to extend the collaboration for further 5 siRNA therapies targeting CV- renal- metabolic and respiratory diseases
• The companies will collaborate during the discovery phase while AstraZeneca will lead clinical development and commercialization of molecules- developed during the collaboration. Silence will get an option to co-develop two programs starting from P-II

Click here ­to­ read full press release/ article 

Ref: Silence Therapeutics  | Image: AstraZeneca